Focus: Cogent Biosciences is a public biotech company focused on cellular immunotherapies and targeted oncology treatments, with a diversified pipeline spanning Phase 1 to Phase 3 programs across oncology and neurology indications.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Contracting — net -38 jobs in 30d
12 added, 50 removed. Active reduction in progress.
Cogent is a high-risk, high-reward bet suited for scientists and commercial professionals comfortable with pre-revenue biotech dynamics but seeking imminent catalysts; aggressive hiring suggests internal confidence in near-term milestones.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cogent Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cogent Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cogent Biosciences submits bezuclastinib new drug application to the FDA - TipRanks
Cogent Biosciences submits bezuclastinib new drug application to the FDA TipRanks
Cogent Biosciences Announces Submission of New Drug - GlobeNewswire
Cogent Biosciences Announces Submission of New Drug GlobeNewswire
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - ChartMill
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) ChartMill
Cogent files new GIST drug after trial cut progression risk 50% - Stock Titan
Cogent files new GIST drug after trial cut progression risk 50% Stock Titan
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - Yahoo Finance
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) Yahoo Finance
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio Update - News and Statistics - IndexBox
Kynam Capital Sells $48M in Cogent Biosciences Shares | Q4 2025 Portfolio Update - News and Statistics IndexBox
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo